Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 1Neoplasms 1Epilepsy 1

Interventions

Everolimus 18Sirolimus 15Cannabidiol 5radiprodil 3ganaxolone 3Vigabatrin 3Activator Appliances 3Melatonin 2exemestane 1dactolisib 1carbon-11 acetate 1Surveys and Questionnaires 1Simvastatin 1Sertraline 1Selective Serotonin Reuptake Inhibitors 1Propranolol 1Itraconazole 1Injections 1Fluid Therapy 1Doxycycline 1Curcumin 1Carbamazepine 1Calcitriol 1Aspirin 1Anticonvulsants 1Actigraphy 1Acceptance and Commitment Therapy 12-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Tuberous Sclerosis × Vigabatrin × Clear all
NCT02849457 2024-08-19

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

University of Alabama at Birmingham

Phase 2 Completed
84 enrolled 16 charts

Tuberous Sclerosis

NCT04987463 2024-02-08

ViRap

Children's Memorial Health Institute, Poland

Phase 2/3 Unknown
60 enrolled

Epilepsy, Neoplasms, Tuberous Sclerosis

NCT01266291 2017-07-12

STARS

University of Pennsylvania

Phase 4 Terminated
1 enrolled 8 charts

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡